Steve Rosenberg has been a life science and healthcare executive for 40+ years and is currently CEO of uMotif. He commercialized the first integrated clinical technology suite at Phase Forward/Oracle. Top pharma and biotech executives depend on him for...
Caroline Jackson is executive vice president for patient services at mdgroup and she will be delivering a presentation at SCOPE called 'Achieving the Impossible: Maximizing Patient Experience and Data Quality in a Complex Rare Disease Program.'...
The Summit for Clinical Ops Executives (SCOPE) is back with a four-day schedule that digs into strategies and technologies for tackling the perpetual problem of patient recruitment.
After a turbulent year in which clinical trial supply teams contended with war, inflation, and more, the Summit for Clinical Ops Executives (SCOPE) is returning with case studies and best practices about how to navigate the challenges...
Canadian CRO Nutrasource Pharmaceutical and Nutraceutical Services Inc has rebranded its clinical trial site as Apex Trials to expand its focus beyond food & natural health product trials.
Thread is one of a number of companies that are trying to address persistent problems with clinical trials such as recruitment and retention through DCT platforms that loosen, and for some programs sever, the link between geographic proximity to study...
Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...
A partnership to put an end to the ‘tremendously manual and time-consuming’ collection of clinical data and medication history has been formed between health information (HIN) Health Gorilla and DrFirst, a healthcare technology solutions consultancy.
Hataali has introduced a new version of its blockchain-based advanced therapy platform to address one of the key supply chain challenges faced by contract manufacturers and pharma companies today.
Evidence shows that animal models currently dominating bioavailability estimates are poor predictors and human, cell-based multi-organ microphysiological systems (MPS) should be investigated, CN Bio says.
Amgen joins the Winn Award Program that was set up by Bristol Myers Squibb, with plans to extend the reach of clinical trials into underserved patient populations in the US.
AMR joins a Series C funding raise for BioVersys, which is developing antimicrobials against common drug-resistant bacteria that threaten public health.
The FDA found traces of a nitrosamine in batches of vonoprazan, delaying the commercialization of the product and its application for an additional indication.
A Florida doctor has been sent to prison after submitting a false affidavit claiming she had screened children in a clinical study looking at the effectiveness of drugs given to children with asthma when she had not.
A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.
The US Food and Drug Administration (FDA) has approved AstraZeneca’s asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.
The not-for-profit organization published its fair inclusion score to measure and rank pharmaceutical companies on their inclusion of women, older adults, and racial and ethnic minoritized patients.
The cryptocurrency space suffered through a torrid, scandal-marked 2022 but there remains interest in using the blockchain infrastructure that underpins the sector in other contexts. In a recent review of the potential of the blockchain in healthcare,...
Digital twins could overcome common data management issues at equipment-intense research facilities, according to a paper published in the journal Sensors.
Turbine will provide its machine learning platform to better understand which cancer types and patient population stand to benefit most from treatment by Cancer Research’s drug candidate.
The health data company emerges promising to revolutionize the real-world data made available to clinical researchers, and to provide the data to the patients themselves.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
After a successful evaluation of its whole-genome sequencing-based test for solid tumor minimal residual disease (MRD) C2i Genomics announced today (January 5) that they have extended their collaboration with AstraZeneca.
The two companies, who had previously established a customer-supplier relationship, have created an agreement to advance the technology and to encourage adoption.
